Safety issues pinpointed earlier with Spotfire's interactive analysis data solution
Safety issues pinpointed earlier with Spotfire's interactive analysis data solution
Spotfire's (Somerville, MA) Clinical Trial Analysis software is built on its DXP enterprise analytics platform for pharmaceutical companies and can be used by physicians, scientists, analysts, and nontechnical staff to discover data relationships related to drug safety and efficacy. This allows companies to address drug design and discovery earlier in the process.
Spotfire Clinical Trial Analysis provides querying capabilities of clinical and molecular data using graphs and charts. It analyzes data from various sources to identify trends, outliers, and exceptions; offers visual representations (charts, plots, graphs) of adverse event data, lab safety, demographics, and concomitant medications; allows for ad hoc data query; finds correlations between gene or protein expressions and safety profiles; and adapts to new technologies and methodologies.
Spotfire, (617) 702-1600, www.spotfire.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.